睾酮治疗与静脉血栓栓塞风险:基于人群的病例对照研究
该研究为基于英国370家全科诊所数据的病例对照研究,纳入19215例确诊静脉血栓栓塞患者和909530名年龄匹配对照。当前使用睾酮者静脉血栓栓塞调整率比为1.25(95%CI 0.94-1.66),未达统计学显著。治疗前6个月内率比为1.63(95%CI 1.12-2.37),对应每万人年额外增加10.0例(95%CI 1.9-21.6),基础率为每万人年15.8例。治疗超过6个月后率比为1.00(95%CI 0.68-1.47),停药后为0.68(95%CI 0.43-1.07)。结论认为开始睾酮治疗与静脉血栓栓塞风险升高相关,风险在6个月内达峰后下降。
要点
- 当前使用睾酮者静脉血栓栓塞调整率比为1.25(95%CI 0.94-1.66),未达统计学显著。
- 睾酮治疗前6个月内静脉血栓栓塞率比为1.63(95%CI 1.12-2.37),对应每万人年额外增加10.0例(95%CI 1.9-21.6),基础率为每万人年15.8例。
- 治疗超过6个月后率比为1.00(95%CI 0.68-1.47),停药后率比为0.68(95%CI 0.43-1.07)。
- 前6个月内率比在病理性格腺功能减退患者中为1.52(95%CI 0.94-2.46),无该情况者为1.88(95%CI 1.02-3.45)。
- 前6个月内率比在已知静脉血栓栓塞危险因素患者中为1.41(95%CI 0.82-2.41),无该因素者为1.91(95%CI 1.13-3.23)。
适用人群与场景
- 英国370家全科诊所数据中2001年1月至2013年5月间超过222万名男性中的确诊静脉血栓栓塞患者(深静脉血栓和肺栓塞)及年龄匹配对照。
研究设计与关键结果
- 研究设计为基于人群的病例对照研究,纳入19215例确诊静脉血栓栓塞患者和909530名年龄匹配对照。
- 当前使用睾酮者静脉血栓栓塞调整率比为1.25(95%CI 0.94-1.66),未达统计学显著。
- 治疗前6个月内静脉血栓栓塞率比为1.63(95%CI 1.12-2.37),对应每万人年额外增加10.0例(95%CI 1.9-21.6),基础率为每万人年15.8例。
- 治疗超过6个月后率比为1.00(95%CI 0.68-1.47),停药后率比为0.68(95%CI 0.43-1.07)。
- 前6个月内率比在病理性格腺功能减退患者中为1.52(95%CI 0.94-2.46),无该情况者为1.88(95%CI 1.02-3.45)。
- 前6个月内率比在已知静脉血栓栓塞危险因素患者中为1.41(95%CI 0.82-2.41),无该因素者为1.91(95%CI 1.13-3.23)。
证据类型、等级与局限
- 证据类型:基于人群的病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 开始睾酮治疗与静脉血栓栓塞风险升高相关,风险在6个月内达峰后下降,提示在启动睾酮治疗的前6个月内需关注静脉血栓栓塞风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine the risk of venous thromboembolism associated with use of testosterone treatment in men, focusing particularly on the timing of the risk.
DESIGN: Population based case-control study SETTING: 370 general practices in UK primary care with linked hospital discharge diagnoses and in-hospital procedures and information on all cause mortality.
PARTICIPANTS: 19 215 patients with confirmed venous thromboembolism (comprising deep venous thrombosis and pulmonary embolism) and 909 530 age matched controls from source population including more than 2.22 million men between January 2001 and May 2013.
EXPOSURE OF INTEREST: Three mutually exclusive testosterone exposure groups were identified: current treatment, recent (but not current) treatment, and no treatment in the previous two years. Current treatment was subdivided into duration of more or less than six months.
MAIN OUTCOME MEASURE: Rate ratios of venous thromboembolism in association with current testosterone treatment compared with no treatment were estimated using conditional logistic regression and adjusted for comorbidities and all matching factors.
RESULTS: The adjusted rate ratio of venous thromboembolism was 1.25 (95% confidence interval 0.94 to 1.66) for current versus no testosterone treatment. In the first six months of testosterone treatment, the rate ratio of venous thromboembolism was 1.63 (1.12 to 2.37), corresponding to 10.0 (1.9 to 21.6) additional venous thromboembolisms above the base rate of 15.8 per 10 000 person years. The rate ratio after more than six months' treatment was 1.00 (0.68 to 1.47), and after treatment cessation it was 0.68 (0.43 to 1.07). Increased rate ratios within the first six months of treatment were observed in all strata: the rate ratio was 1.52 (0.94 to 2.46) for patients with pathological hypogonadism and 1.88 (1.02 to 3.45) for those without it, and 1.41 (0.82 to 2.41) for those with a known risk factor for venous thromboembolism and 1.91 (1.13 to 3.23) for those without one.
CONCLUSIONS: Starting testosterone treatment was associated with an increased risk of venous thromboembolism, which peaked within six months and declined thereafter.
参考来源
- Martinez C, Suissa S, Rietbrock S, et al. Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ. 2016. PMID: 27903495. doi:10.1136/bmj.i5968
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。